Takeda Pharmaceutical (TAK) Depreciation & Amortization (CF) (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Depreciation & Amortization (CF) of $1.0 billion for Q2 2026, down 18.51% year-over-year from $1.3 billion in Q2 2025, and down 2.11% quarter-over-quarter from $1.0 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $1.0 billion for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) fell 18.51% year-over-year to $1.0 billion; the TTM figure through Jun 2026 stood at $4.6 billion (down 9.11% YoY), while the FY2026 annual figure was $4.8 billion, down 4.16% from the prior year.
- Depreciation & Amortization (CF) for Q2 2026 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.3 billion in Q1 2022, with the low at $1.0 billion in Q2 2026.
- The 5-year median for Depreciation & Amortization (CF) is $1.2 billion (2025), against an average of $1.2 billion.
- The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) grew 4.11% in 2023, then fell 18.51% in 2026.
- Takeda Pharmaceutical's Depreciation & Amortization (CF) stood at $1.3 billion in 2022, then climbed by 1.08% to $1.3 billion in 2023, then declined by 2.83% to $1.2 billion in 2024, then increased by 0.73% to $1.2 billion in 2025, then retreated by 17.42% to $1.0 billion in 2026.
- Business Quant data shows TAK's Depreciation & Amortization (CF) at $1.0 billion in Q2 2026, $1.0 billion in Q1 2026, and $1.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 30.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Bn |
| Jun 30, 2026 | 1.02 Bn |
| Mar 31, 2026 | 1.04 Bn |
| Mar 31, 2026 | 1.04 Bn |
| Dec 31, 2025 | 1.24 Bn |
| Dec 31, 2025 | 1.24 Bn |
| Sep 30, 2025 | 1.26 Bn |
| Sep 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.26 Bn |
| Mar 31, 2025 | 1.24 Bn |
| Mar 31, 2025 | 1.24 Bn |
| Dec 31, 2024 | 1.23 Bn |
| Dec 31, 2024 | 1.23 Bn |
| Sep 30, 2024 | 1.29 Bn |
| Sep 30, 2024 | 1.29 Bn |
| Jun 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.23 Bn |
| Mar 31, 2024 | 1.26 Bn |
| Mar 31, 2024 | 1.26 Bn |